The same TriMix-DC-MEL vaccine, based on mRNA coding for four melanoma-associated antigens (tyrosinase, gp100, MAGE-A3, and MAGE-C2), has been also combined with ipilimumab administration in 30 advanced melanoma patients [46]. This evidence concerns the gene MAGEC2 and melanoma.